Navigation Links
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Date:10/15/2008

12 Patient Trial Targets Advanced Solid Tumors, Including Lung Cancer

SAN FRANCISCO, Oct. 15 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) today announced the completion of treatment for the first patient cohort in the Phase 1 cancer clinical trial of its targeted poxvirus JX-594, delivered by intravenous (IV) infusion. No significant toxicities were reported, and treatment was well-tolerated.

The Phase 1 IV trial involves treatment of patients with advanced, metastatic solid tumors refractory to standard therapy. Patients receive treatment at one of five dose levels in a sequential dose-escalating design; the first cohort has now been treated safely. Once the maximum tolerated dose is defined, an additional three to six patients will be enrolled at that dose level. The trial is being conducted initially at clinical sites in the United States, and will subsequently open at sites in Canada. "We're very excited to have this trial open and enrolling with our lead product, JX-594. The safe delivery of JX-594 through intravenous administration is a major milestone for our Company," said David H. Kirn, M.D., President and Chief Executive Officer of Jennerex. "IV therapy allows treatment of major market cancers including non-small cell lung cancer. These data confirm the safety and feasibility of systemic dosing and tumor targeting that were reported in liver tumor patients treated previously."

The primary objective for this trial is to determine the maximum tolerated and/or feasible dose of JX-594 administered IV. In addition, IV delivery of JX-594 to solid tumors will be evaluated. An estimated total of 12 to 15 patients will be treated.

About JX-594

JX-594 is a cancer biotherapeutic product, currently in Phase 2 trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types on three Phase 1 trials; treat
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... announced today the presentation of results from a new ... among diabetic patients in the U.S. than previously recognized. ... both type 1 and type 2 diabetes, but this ... common type 2 disease. Lee ... Medicine at Harvard Medical School and Director of the ...
(Date:5/20/2013)... Mass. , May 20, 2013 ... and advisory firms for pharmaceutical and healthcare issues, ... that therapies offering a greater effect on quality ... unmet need. Given the high level of subjectivity ... of life, interviewed thought leaders state that it ...
(Date:5/19/2013)...  The non-surgical Stretta® procedure employing ... is effective in control of gastroesophageal reflux disease ... medication 10 years post-procedure, according to an independent, ... Disease Week (DDW) meeting May 18-21, 2013 in ... "The sustained improvement in GERD-HRQL scores and ...
Breaking Medicine Technology:Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3
... Terumo Heart, Inc. announced,today that it ... the European,Association of Cardio-Thoracic Surgeons (EACTS) meeting ... ) (Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO ) ... Trial results for the DuraHeart(TM),Left Ventricular Assist ...
... analysis reported,at the American Society for Bone and ... decreased clinical fracture risk by 50% over,three years ... women with,osteoporosis who had suffered a previous hip ... evaluated the combined incidence,of vertebral and nonvertebral clinical ...
Cached Medicine Technology:Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 3Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 4
(Date:5/20/2013)... For the third consecutive year, ... Frederick Award in the Professional Standards Review Board ... The USCA "Best of Local Business" Award Program ... year, the USCA identifies companies that they believe ... community and business category. These are local companies ...
(Date:5/20/2013)... When people have lap ... become a celebrity. New Jersey governor Chris Christie, ... report (“Chris Christie Says Lap Band Surgery Is ... surgery was not done so that he could ... as a former lap band patient. Simply put, ...
(Date:5/20/2013)... The new healthcare bill proposes to ... all Americans. However, not all the conditions were to ... might take up to 2014 to show anything. ... states are currently moving forward to implement the health ... Iowa, Michigan, New Hampshire, and West Virginia. HHS will ...
(Date:5/20/2013)... May 20, 2013 Dr. Robert Mokbel ... and trained to use the Laser Assisted New Attachment ... treat patients with gum disease. LANAP may help many ... to gum disease restore the jawbone support necessary to ... buildup of plaque and tartar in the mouth. Daily ...
(Date:5/20/2013)... May 20, 2013 Daily Gossip, online magazine ... its readers with useful tips that can help them overcome ... According to the website Natural Vitiligo Treatment System ... numerous positive reviews it has received from the persons who ... now, but Daily Gossip has interviewed some of the people ...
Breaking Medicine News(10 mins):Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Review of Health Bill Impact in 2014 2Health News:Review of Health Bill Impact in 2014 3Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2
... less likely than Caucasian patients to undergo coronary ... successful angioplasty, a type of percutaneous coronary intervention ... Hispanics also had a trend toward lower ... and bypass surgery, according to a study presented ...
... especially true for blacks, study suggests , , SUNDAY, Nov. ... as big a risk factor for high blood pressure as ... , The study also identified a gene that may ... based on a Texas heart study done on the urine ...
... ATLANTA The 2008 Joint Meeting of the American Academy ... ), the largest and most comprehensive ophthalmic educational meeting ... 8 to 11 at the Georgia World Congress Center, ... 179 "Breakfast with the Experts" roundtables, 95 skills transfer ...
... side effects , , SATURDAY, Nov. 8 (HealthDay News) -- ... of the blood thinner warfarin significantly reduces the risk ... a University of Pennsylvania School of Medicine study. , ... doctor and fill their prescription at a single pharmacy ...
... WASHINGTON, Nov. 7 Ninety years ago today,the guns fell ... end all wars" -,was over. Almost five million Americans served ... them, 107-year-old Army veteran,Frank Buckles, observes this Veterans Day at ... Veterans Day, for all Americans to reflect on the,service and ...
... , , FRIDAY, Nov. 7 (HealthDay News) -- Dialysis ... reduced the risk of death for kidney patients by ... times a week, a new study found. , This ... lead author said. "Unfortunately, the mortality rate of patients ...
Cached Medicine News:Health News:Hispanics less likely to have repeat revascularizations 1 year after angioplasty 2Health News:Lack of Potassium Linked to High Blood Pressure 2Health News:AAO-SOE Joint Meeting research highlights 2Health News:AAO-SOE Joint Meeting research highlights 3Health News:AAO-SOE Joint Meeting research highlights 4Health News:Written Instructions Cut Bleeding Risk for Blood Thinner Use 2Health News:A Veterans Day Message From VA Secretary Dr. James B. Peake 2Health News:A Veterans Day Message From VA Secretary Dr. James B. Peake 3Health News:A Veterans Day Message From VA Secretary Dr. James B. Peake 4Health News:Overnight Dialysis Saves Lives: Study 2Health News:Overnight Dialysis Saves Lives: Study 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: